BamSEC and AlphaSense Join Forces
Learn More

Alaunos Therapeutics Inc. – Indentures

NASDAQ: TCRT    
Share price (3/27/26): $2.98    
Market cap (3/27/26): $6.651 million
Search in Documents
Key Exhibits
External Links

Indentures Filter

EX-4
from SCHEDULE 13D/A Indenture or similar
12/34/56
EX-4
from SCHEDULE 13D Indenture or similar
12/34/56
EX-4.10
from S-3/A 41 pages Alaunos Therapeutics, Inc. Issuer and [Trustee], Trustee Indenture Dated as of , 20
12/34/56
EX-4.1
from 8-K 14 pages Pre-Funded Warrant to Purchase Common Stock of Alaunos Therapeutics, Inc
12/34/56
EX-4.1
from 8-K 3 pages Amendment #1 to the Common Stock Purchase Warrant Issued on May 19, 2025
12/34/56
EX-4.6
from S-3 20 pages Alaunos Therapeutics, Inc. and , as Warrant Agent Form of Debt Securities Warrant Agreement Dated as of Alaunos Therapeutics, Inc. Form of Debt Securities Warrant Agreement
12/34/56
EX-4.5
from S-3 22 pages Alaunos Therapeutics, Inc. and , as Warrant Agent Form of Preferred Stock Warrant Agreement Dated as of Alaunos Therapeutics, Inc. Form of Preferred Stock Warrant Agreement Article 1 Issuance of Warrants and Execution and Delivery of Warrant Certificates
12/34/56
EX-4.4
from S-3 21 pages Alaunos Therapeutics, Inc. and , as Warrant Agent Form of Common Stock Warrant Agreement Dated as of Alaunos Therapeutics, Inc. Form of Common Stock Warrant Agreement Article 1 Issuance of Warrants and Execution and Delivery of Warrant Certificates
12/34/56
EX-4.2
from S-3 54 pages Alaunos Therapeutics, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [•], 20 Debt Securities
12/34/56
EX-4.7
from 10-K 4 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.6
from 10-K 12 pages Amended and Restated Warrant to Purchase Stock
12/34/56
EX-4.1
from 10-Q 12 pages Warrant to Purchase Stock
12/34/56
EX-4.8
from 10-K 3 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.7
from 10-K 15 pages Certain Confidential Information Contained in This Document, Marked by [*****], Has Been Omitted Because Ziopharm Oncology, Inc. Has Determined the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to Ziopharm Oncology, Inc. if Publicly Disclosed
12/34/56
EX-4.1
from 8-K 13 pages Ziopharm Oncology, Inc. Warrant to Purchase Common Stock
12/34/56
EX-4.1
from 8-K 14 pages Ziopharm Oncology, Inc. Warrant to Purchase Common Stock
12/34/56
EX-4.7
from S-3ASR 18 pages Ziopharm Oncology, Inc. and , as Warrant Agent Form of Debt Securities Warrant Agreement Dated as of Ziopharm Oncology, Inc. Form of Debt Securities Warrant Agreement
12/34/56
EX-4.6
from S-3ASR 20 pages Ziopharm Oncology, Inc. and , as Warrant Agent Form of Preferred Stock Warrant Agreement Dated as of Ziopharm Oncology, Inc. Form of Preferred Stock Warrant Agreement Article 1 Issuance of Warrants and Execution and Delivery of Warrant Certificates
12/34/56
EX-4.5
from S-3ASR 20 pages Ziopharm Oncology, Inc. and , as Warrant Agent Form of Common Stock Warrant Agreement Dated as of Ziopharm Oncology, Inc. Form of Common Stock Warrant Agreement Article 1 Issuance of Warrants and Execution and Delivery of Warrant Certificates
12/34/56
EX-4.3
from S-3ASR 55 pages Ziopharm Oncology, Inc., Issuer and [Trustee], Trustee Indenture Dated as of [•], 20 Debt Securities
12/34/56